As an FDA official said that the agency has evidence that links COVID vaccines to the deaths of at least 10 children, the U.S ...

Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems have been reported.

U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective ...

In this morning's Pharmalittle roundup, we're reading about FDA scrutiny of RSV therapies, an AI tool for clinical trials, ...

The FDA has informed Merck, Sanofi and AstraZeneca of the safety investigation into their RSV antibodies, though it remains ...

Respiratory syncytial virus remains a leading cause of infant hospitalisation, making awareness and prevention essential for ...

Company planning for every eligible baby in the US to have access to BEYFORTUS New BEYFORTUS filling line approved by the U.S. Food and Drug Administration (FDA) to expand manufacturing capacity and ...

The agency also is reviewing safety of immunizations for RSV, according to manufacturers of the therapies who have been ...

We’re sorry, we are currently experiencing some issues, please try again later. Our team is working diligently to resolve the issue. Thank you for your patience and ...

Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which typically ...